EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker

Benjamin N Schmeusser iD, Henry Biermann, Edouard H Nicaise, Adil A Ali, Dattatraya H Patil, Eric Midenberg, Talia Helman, Manuel Armas-Phan, Reza Nabavizadeh, Shreyas S Joshi, Vikram M Narayan, Mehmet A Bilen und 3 weitere

The Oncologist · 11.12.2023 · 28 (12) · e1219-e1229

DOI: 10.1093/oncolo/oyad218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 04.08.2023. Verfasst von Benjamin N Schmeusser und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Sarcopenia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: John Robinson Family Foundation, Christopher Churchill Foundation, Cox Immunology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Low creatinine to cystatin-C ratio (Cr/Cys-C) may be a biomarker for low-muscle mass. Furthermore, low Cr/Cys-C is associated with decreased overall survival (OS), but to date, has not been examined in patients with renal cell carcinoma (RCC). Our objective is to evaluate associations between low Cr/Cys-C ratio and OS and recurrence-free survival (RFS) in patients with RCC treated with nephrectomy.

Methods

We performed a retrospective review of patients with RCC treated with nephrectomy. Patients with end-stage renal disease and less than 1-year follow up were excluded. Cr/Cys-C was dichotomized at the median for the cohort (low vs. high). OS and RFS for patients with high versus low Cr/Cys-C were estimated with the Kaplan-Meier method, and associations with the outcomes of interest were modeled using Cox proportional Hazards models. Associations between Cr/Cys-C and skeletal muscle mass were assessed with correlations and logistic regression.

Results

A total of 255 patients were analyzed, with a median age of 64. Median (IQR) Cr/Cys-C was 1 (0.8-1.2). Low Cr/Cys-C was associated with age, female sex, Eastern Cooperative Oncology Group Performance Status ≥1, TNM stage, and tumor size. Kaplan-Meier and Cox regression analysis demonstrated an association between low Cr/Cys-C and decreased OS (HR = 2.97, 95%CI, 1.12-7.90, P =0.029) and RFS (HR = 3.31, 95%CI, 1.26-8.66, P = .015). Furthermore, a low Cr/Cys-C indicated a 2-3 increase in risk of radiographic sarcopenia.

Conclusions

Lower Cr/Cys-C is associated with inferior oncologic outcomes in RCC and, pending validation, may have utility as a serum biomarker for the presence of sarcopenia in patients with RCC treated with nephrectomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsSarcopeniaHumansFemaleCreatininePrognosisBiomarkersRetrospective Studies

Stichwörter der Autor:innen

biomarkerbody compositionnephrectomyrenal cell carcinoma (RCC)sarcopeniasurvival

Substanzen

CreatinineBiomarkers

Autor:innen und Institutionen

  • Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.
  • Department of Urology, University of Louisville, Louisville, KY, USA.
  • Department of Urology, Mayo Clinic, Rochester, MN, USA.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
  • Department of Urology, University of Washington, Seattle, WA, USA.

ORCID-Profile: Benjamin N Schmeusser, Sarah P Psutka

Förderung

  • John Robinson Family Foundation
  • Christopher Churchill Foundation
  • Cox Immunology

Zitieren

APA

Schmeusser, B. N., Biermann, H., Nicaise, E. H., Ali, A. A., Patil, D. H., Midenberg, E., Helman, T., Armas-Phan, M., Nabavizadeh, R., Joshi, S. S., Narayan, V. M., Bilen, M. A., Psutka, S. P., Ogan, K., & Master, V. A. (2023). Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker. The Oncologist, 28(12), e1219-e1229. https://doi.org/10.1093/oncolo/oyad218

Vancouver

Schmeusser BN, Biermann H, Nicaise EH, Ali AA, Patil DH, Midenberg E, et al. Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker. The Oncologist. 2023;28(12):e1219-e1229. doi:10.1093/oncolo/oyad218

BibTeX
@article{Schmeusser2023,
  author = {Schmeusser, Benjamin N and Biermann, Henry and Nicaise, Edouard H and Ali, Adil A and Patil, Dattatraya H and Midenberg, Eric and Helman, Talia and Armas-Phan, Manuel and Nabavizadeh, Reza and Joshi, Shreyas S and Narayan, Vikram M and Bilen, Mehmet A and Psutka, Sarah P and Ogan, Kenneth and Master, Viraj A},
  title = {Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {12},
  pages = {e1219--e1229},
  doi = {10.1093/oncolo/oyad218}
}
Kostenlos starten →